About Us
Equillium is a clinical-stage biotechnology company leveraging a deep
understanding of immunobiology to develop novel therapeutics to treat
severe autoimmune and inflammatory disorders with high unmet medical need.
The company’s pipeline consists of the following novel immunomodulatory
assets targeting immuno-inflammatory pathways. Itolizumab, a
first-in-class monoclonal antibody that targets the CD6-ALCAM signaling
pathway which plays a central role in the modulation of effector T cells,
is currently in a
Phase 3 study for patients with acute graft-versus-host
disease (aGVHD) and is in a Phase 1b study for patients with lupus/lupus
nephritis. EQ101, a first-in-class tri-specific cytokine inhibitor that
selectively targets IL-2, IL-9, and IL-15, is Phase 2 ready and expected
to begin enrolling patients in an alopecia areata study in the second half
of 2022. EQ102, a bi-specific cytokine inhibitor that selectively targets
IL-15 and IL-21, is ready for clinical development and expected to begin
enrolling in a Phase 1 study in patients with celiac disease in the second
half of 2022.